Y Intercept Hong Kong Ltd Invests $102,000 in OPKO Health, Inc. (NASDAQ:OPK)

Y Intercept Hong Kong Ltd bought a new stake in OPKO Health, Inc. (NASDAQ:OPK) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 69,591 shares of the biotechnology company’s stock, valued at approximately $102,000.

Several other hedge funds have also bought and sold shares of OPK. Rubric Capital Management LP raised its stake in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after buying an additional 4,284,336 shares during the period. Barclays PLC increased its holdings in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares during the last quarter. BNP Paribas Financial Markets raised its stake in OPKO Health by 736.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 217,450 shares during the period. Intech Investment Management LLC bought a new stake in OPKO Health in the 3rd quarter valued at $190,000. Finally, FMR LLC lifted its holdings in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 150,000 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was purchased at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the transaction, the chief executive officer now owns 213,186,477 shares in the company, valued at $313,384,121.19. The trade was a 0.07 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired a total of 1,389,971 shares of company stock worth $2,124,442 in the last quarter. Corporate insiders own 47.26% of the company’s stock.

OPKO Health Stock Up 1.0 %

OPK stock opened at $1.94 on Thursday. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -10.21 and a beta of 1.63. The business’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $1.55.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on OPK. Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday. Finally, StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.